Aspire BioPharma, Inc. (ASBP) Balance Sheet
ASBP balance sheet, 2025
December 31, 2025 · U.S. dollars$1.3M assets = $7.7M liabilities + −$6.4M equity
Liabilities exceed assets: shareholders’ equity is negative (−$6.4M).
Both columns are drawn to the same scale: what ASBP owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ASBP financial health
Descriptive bands, not a rating. Fiscal 2025.
ASBP balance sheet trends, 2021–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $293,2212021 | $1.3M2025 | +45.4%/yr | |
| Total liabilities | $293,6962021 | $7.7M2025 | +126.2%/yr | |
| Shareholders’ equity | −$4752021 | −$6.4M2025 | — | |
| Cash & short-term investments | $497,2592022 | $1.0M2025 | +26.4%/yr | |
| Total debt | $238,5962021 | $1.4M2025 | +55.2%/yr | |
| Net cash (debt) | −$238,5962021 | −$380,8742025 | −$142,278 | |
| Working capital | −$4752021 | −$6.3M2025 | −$6.3M | |
| Book value per share | −$0.002021 | −$4.272025 | — | |
| Current ratio | 1.002021 | 0.172025 | −0.83 | |
| Debt / equity | 0.002022 | 0.002023 | 0.00 | |
| Shares outstanding | 683K2021 | 1.5M2025 | +21.6%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ASBP assets
ASBP liabilities and equity
ASBP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ASBP balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & short-term investments | $1.0M | $3,633 | $11,174 | $497,259 | — |
| Cash & equivalents | $1.0M | $3,633 | $11,174 | $497,259 | — |
| Receivables | $0 | $36,503 | $0 | $0 | $0 |
| Inventory | $253,160 | $0 | $0 | $0 | $0 |
| Other current assets | $55,102 | $107,853 | $70,049 | $600,493 | $293,221 |
| Total current assets | $1.3M | $147,989 | $81,223 | $1.1M | $293,221 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $19.9M | $299.1M | $0 |
| Total assets | $1.3M | $147,989 | $20.0M | $300.2M | $293,221 |
| Liabilities | |||||
| Accounts payable | $1.0M | $310,219 | $152,005 | $180,634 | $273 |
| Short-term debt | $1.4M | $1.3M | $12,384 | $27,967 | $238,596 |
| Deferred revenue | — | — | — | $80 | — |
| Total current liabilities | $7.6M | $1.7M | $403,328 | $303,323 | $293,696 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $95,662 | $0 | $0 | $10.8M | $0 |
| Total liabilities | $7.7M | $1.7M | $403,328 | $11.1M | $293,696 |
| Shareholders' equity | |||||
| Common stock & paid-in capital | $353 | $69 | $19.9M | $299.0M | $718 |
| Retained earnings (deficit) | −$27.3M | −$2.8M | −$11.3M | −$9.9M | −$25,475 |
| Accumulated other comprehensive income | — | — | $0 | — | — |
| Total shareholders' equity | −$6.4M | −$1.5M | $19.6M | $289.1M | −$475 |
| Key figures | |||||
| Total debt | $1.4M | $1.3M | $12,384 | $27,967 | $238,596 |
| Net cash (debt) | −$380,874 | −$1.3M | −$1,210 | $469,292 | −$238,596 |
| Working capital | −$6.3M | −$1.5M | −$322,105 | $794,429 | −$475 |
| Tangible book value | −$6.4M | −$1.5M | $19.6M | $289.1M | −$475 |
| Book value per share | −$4.27 | — | $40.83 | $321.74 | −$0.00 |
| Shares outstanding | 1.5M | — | 479K | 898K | 683K |
| Current ratio | 0.17 | 0.09 | 0.20 | 3.62 | 1.00 |
| Quick ratio | 0.13 | 0.02 | 0.03 | 1.64 | 0.00 |
| Debt / equity | — | — | 0.00 | 0.00 | — |
| Equity / assets | −485.9% | −1,040.7% | 98.0% | 96.3% | −0.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $12.2M | $5.9M | $1.0M | $1.9M | $206,233 | $1.3M | $3,633 | $6.6M | $19,604 | — | $11,174 | $280 |
| Cash & equivalents | $12.2M | $5.9M | $1.0M | $1.9M | $206,233 | $1.3M | $3,633 | $6.6M | $19,604 | — | $11,174 | $280 |
| Receivables | $0 | $0 | $0 | $0 | $0 | $36,503 | $36,503 | $25,034 | $299,921 | $0 | $0 | $0 |
| Inventory | $288,450 | $369,974 | $253,160 | $35,437 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $1.0M | $890,149 | $55,102 | $419,421 | $783,189 | $582,468 | $107,853 | $0 | $0 | $65,577 | $70,049 | $253,082 |
| Total current assets | $13.5M | $7.1M | $1.3M | $2.4M | $989,422 | $2.0M | $147,989 | $61,809 | $49,604 | $65,577 | $81,223 | $253,362 |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5.0M | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $75,000 | $0 | $0 | $0 | $0 | $0 | $0 | $6.6M | $0 | $20.1M | $19.9M | $19.6M |
| Total assets | $13.5M | $7.1M | $1.3M | $2.4M | $989,422 | $2.0M | $147,989 | $6.7M | $5.1M | $20.2M | $20.0M | $19.9M |
| Liabilities | ||||||||||||
| Accounts payable | $972,108 | $857,925 | $1.0M | $1.1M | $1.4M | $1.4M | $310,219 | $903,687 | $161,529 | $365,010 | $152,005 | $104,379 |
| Short-term debt | — | $1.5M | $5.2M | $8.6M | $8.5M | $6.8M | $1.3M | $436,284 | $445,408 | $2.0M | $12,384 | — |
| Total current liabilities | $1.7M | $3.2M | $7.6M | $13.9M | $10.6M | $8.9M | $1.7M | $6.6M | $764,276 | $2.6M | $403,328 | $316,316 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $96,527 | $96,252 | $95,662 | $9,901 | $49,285 | $49,303 | $0 | $0 | $3.9M | $487,861 | $0 | $0 |
| Total liabilities | $1.8M | $3.2M | $7.7M | $13.9M | $10.6M | $8.9M | $1.7M | $6.6M | $4.6M | $2.6M | $403,328 | $316,316 |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $129 | $17 | $353 | $4,953 | $4,953 | $4,890 | $22,000 | $6.6M | $221,661 | $20.1M | $19.9M | $19.6M |
| Retained earnings (deficit) | −$31.7M | −$30.5M | −$27.3M | −$22.6M | −$20.7M | −$18.7M | −$2.8M | −$15.4M | −$1.8M | −$14.0M | −$11.3M | −$10.9M |
| Total shareholders' equity | $11.8M | $3.9M | −$6.4M | −$11.5M | −$9.6M | −$7.0M | −$1.5M | $90,285 | $442,041 | $17.6M | $19.6M | $19.6M |
| Key figures | ||||||||||||
| Total debt | — | $1.5M | $5.2M | $8.6M | $8.5M | $6.8M | $1.3M | $436,284 | $445,408 | $2.0M | $12,384 | — |
| Net cash (debt) | — | $4.4M | −$4.2M | −$6.7M | −$8.3M | −$5.4M | −$1.3M | $6.2M | −$425,804 | −$2.0M | −$1,210 | — |
| Working capital | $11.8M | $4.0M | −$6.3M | −$11.5M | −$9.6M | −$6.9M | −$1.5M | −$6.5M | −$714,672 | −$2.6M | −$322,105 | −$62,954 |
| Tangible book value | $11.8M | $3.9M | −$6.4M | −$11.5M | −$9.6M | −$7.0M | −$1.5M | $90,285 | −$4.6M | $17.6M | $19.6M | $19.6M |
| Book value per share | $11.33 | $2.59 | −$4.27 | −$9.26 | −$7.80 | −$7.34 | — | $0.08 | $0.64 | — | — | — |
| Shares outstanding | 1.0M | 1.5M | 1.5M | 1.2M | 1.2M | 947K | — | 1.2M | 690K | — | — | — |
| Current ratio | 7.99 | 2.26 | 0.17 | 0.17 | 0.09 | 0.22 | 0.09 | 0.01 | 0.06 | 0.02 | 0.20 | 0.80 |
| Quick ratio | 7.22 | 1.86 | 0.13 | 0.14 | 0.02 | 0.16 | 0.02 | 1.01 | 0.42 | 0.00 | 0.03 | 0.00 |
| Debt / equity | — | 0.39 | — | — | — | — | — | 4.83 | 1.01 | 0.11 | 0.00 | — |
| Equity / assets | 86.8% | 54.4% | −485.9% | −477.2% | −972.0% | −353.7% | −1,040.7% | 1.4% | 8.7% | 87.0% | 98.0% | 98.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 30, 2026); data from EODHD.
ASBP financial position
At the end of fiscal 2025 (December 31, 2025), Aspire BioPharma had total assets of $1.3 million (up 786.7% from a year earlier), total liabilities of $7.7 million and shareholders' equity of -$6.4 million. It held $1.0 million in cash and short-term investments against $1.4 million of debt, net debt of $0.4 million. Its current ratio was 0.17. In the latest quarter (ended June 30, 2026) total assets were $13.5 million and equity $11.8 million.
Related: ASBP income statement, ASBP cash flow statement, ASBP key metrics. See the ASBP stock overview for the latest quote and news.
ASBP balance sheet FAQ
What are Aspire BioPharma's total assets?
Aspire BioPharma reported total assets of $1.3 million at the end of fiscal 2025 (December 31, 2025), compared with $0.1 million a year earlier.
How much debt does Aspire BioPharma have?
Aspire BioPharma had $1.4 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was —.
How much cash does Aspire BioPharma have?
Aspire BioPharma held $1.0 million in cash and short-term investments at the end of fiscal 2025; with $1.4 million of debt that is net debt of $0.4 million.
What is Aspire BioPharma's book value?
Aspire BioPharma's shareholders' equity (book value) was -$6.4 million at the end of fiscal 2025, or −$4.27 per share.
What is Aspire BioPharma's current ratio?
Aspire BioPharma had current assets of $1.3 million and current liabilities of $7.6 million, a current ratio of 0.17 (current liabilities exceed current assets).